background: gonadotrophin-releasing hormone (gnrh) agonist is used for controlling ovarian stimulation in assisted reproductive technology (art) cycles which has some benefits. objective: to compare the efficacy of two different formulations of gnrh agonist: short-acting and long-acting, for art protocols. materials and methods: in a prospective randomized study, one hundred women who underwent...

BACKGROUND With the continuous improvement of surgery and chemotherapeutic treatments, many tumour patients increasingly achieve long-term survival and can even be completely cured. However, platinum-containing drugs, which are widely used to treat a variety of types of cancer, cause menstrual disorders and ovarian failure, which in turn lead to infertility. Thus far, gonadotropin releasing hor...

Adolescents with gender dysphoria experience incongruence between their assigned and their experienced gende [1]. Gender reassignment therapy aims to achieve transition to the desired gender and includes psychological, hormonal and surgical interventions. Puberty can be suspended using gonadotropin releasing hormone analogues (GnRHa) thus preventing development in the direction of the natal gen...

and 6.78 at baseline, and 4.41 ug l−1, 168.5 ug l−1, and 26.40 after human chorionic gonadotropin (HCG) stimulation, respectively. Other hypothalamic-pituitary-axes' functions were normal. The patient was treated with HCG 2000 U i.m. 3 times every week for 9 months, and then human menopausal gonadotropin (HMG) 75 U i.m. was added 3 times a week for another 3 months. Mild Dear Editor, Kallmann s...

BACKGROUND The purpose of this study was to determine optimal adjuvant therapy between complete hormonal blockade in premenopausal patients with hormone receptor positive breast cancer and one to three positive nodes. PATIENTS AND METHODS We randomised 333 patients to receive either LHRH agonist (triptorelin 3.75 mg i.m., monthly) plus tamoxifen 30 mg/day for 3 years (TAM-LHRHa, n=164), or fl...

Objective: To assess the effect of GnRHa as luteal phase support in women undergoing controlled ovarian stimulation and IUI. Design: A prospective, randomized trial. Setting: Cytogenetic and Endoscopy Unit, Zagazig University Hospital. Methods: Two hundred fourteen women either with unexplained or mild male factor infertility was planned to contribute to this study. After exclusion 18 women, 19...